Effects ofSTAT3polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR‐mutation positive non‐small cell lung cancer-Reference-Cited by-同舟云学术

Effects ofSTAT3polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR‐mutation positive non‐small cell lung cancer

Published:2020-05-13 Issue:4 Volume:45 Page:652-659
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Yokota Hayato¹^ORCID,Sato Kazuhiro²,Sakamoto Sho²,Okuda Yuji²,Asano Mariko²,Takeda Masahide²,Nakayama Katsutoshi²,Miura Masatomo¹^ORCID

Affiliation:

1. Department of Pharmacy Akita University Hospital Akita Japan

2. Division of Respiratory Medicine Department of Internal Medicine Akita University School of Medicine Akita Japan

Funder

Japan Society for the Promotion of Science London

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13173

Reference28 articles.

1. Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

2. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

3. The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib

4. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival

5. A limited sampling strategy for estimation of the area under the plasma concentration‐time curve of gefitinib;Miura M;Ther Drug Monit,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of p450 Polymorphisms on the Clinical Outcomes of Gefitinib Treatment in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer;Genetic Testing and Molecular Biomarkers;2022-12-01

2. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer;Drug Resistance Updates;2022-05